Shots:

• Under the terms of the agreement, Axantia will be responsible for registration & get the commercialization rights of Intas’ ranibizumab biosimilar referencing Lucentis in territories inc. Saudi Arabia, Jordan, Iraq, Lebanon & GCC countries through its pharmaceutical subsidiaries, pharma international pharmaceutical & chemical manufacturing, and Med City pharmaceutical industries
• Intas' Ranibizumab biosimilar is currently under the P-III trial while Intas plans to submit for approval in the EU and the US
• Ranibizumab is a recombinant humanized IgG1 mAb fragment that binds to & inhibits VEGF-A. It is used for the treatment of wet AMD, RVO, DME, DR, and mCNV

Ref: PR Newswire | Image: Intas